TY - JOUR
T1 - Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP)
AU - Menon, Usha
AU - Weller, David
AU - Falborg, Alina Zalounina
AU - Jensen, Henry
AU - Butler, John
AU - Barisic, Andriana
AU - Knudsen, Anne Kari
AU - Bergin, Rebecca
AU - Brewster, David H.
AU - Cairnduff, Victoria
AU - Fourkala, Evangelia Ourania
AU - Gavin, Anna
AU - Grunfeld, Eva
AU - Harland, Elizabeth
AU - Kalsi, Jatinderpal
AU - Law, Rebecca Jane
AU - Lin, Yulan
AU - Turner, Donna
AU - Neal, Richard D.
AU - White, Victoria
AU - Harrison, Samantha
AU - Reguilon, Irene
AU - Lynch, Charlotte
AU - Vedsted, Peter
AU - Barisic, Andriana
AU - Gavin, Anna
AU - Hawryluk, Breann
AU - Anandan, Chantelle
AU - Donnelly, Conan
AU - Jensen, Henry
AU - Boylan, Jackie
AU - Kelly, Jacqueline
AU - Moore, Kerry
AU - Davis, Maria Rejmyr
AU - Malmberg, Martin
AU - Lambe, Mats
AU - Bucher, Oliver
AU - Vedsted, Peter
AU - Bergin, Rebecca
AU - Almberg, Sigrun Saur
AU - Kearney, Therese
AU - Kalsi, Tindie
AU - Hammersley, Victoria
AU - ICBP Module 4 Working Group
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022
Y1 - 2022
N2 - Background: International Cancer Benchmarking Partnership Module 4 reports the first international comparison of ovarian cancer (OC) diagnosis routes and intervals (symptom onset to treatment start), which may inform previously reported variations in survival and stage. Methods: Data were collated from 1110 newly diagnosed OC patients aged >40 surveyed between 2013 and 2015 across five countries (51–272 per jurisdiction), their primary-care physicians (PCPs) and cancer treatment specialists, supplement by treatment records or clinical databases. Diagnosis routes and time interval differences using quantile regression with reference to Denmark (largest survey response) were calculated. Results: There were no significant jurisdictional differences in the proportion diagnosed with symptoms on the Goff Symptom Index (53%; P = 0.179) or National Institute for Health and Care Excellence NG12 guidelines (62%; P = 0.946). Though the main diagnosis route consistently involved primary-care presentation (63–86%; P = 0.068), onward urgent referral rates varied significantly (29–79%; P < 0.001). In most jurisdictions, diagnostic intervals were generally shorter and other intervals, in particular, treatment longer compared to Denmark. Conclusion: This study highlights key intervals in the diagnostic pathway where improvements could be made. It provides the opportunity to consider the systems and approaches across different jurisdictions that might allow for more timely ovarian cancer diagnosis and treatment.
AB - Background: International Cancer Benchmarking Partnership Module 4 reports the first international comparison of ovarian cancer (OC) diagnosis routes and intervals (symptom onset to treatment start), which may inform previously reported variations in survival and stage. Methods: Data were collated from 1110 newly diagnosed OC patients aged >40 surveyed between 2013 and 2015 across five countries (51–272 per jurisdiction), their primary-care physicians (PCPs) and cancer treatment specialists, supplement by treatment records or clinical databases. Diagnosis routes and time interval differences using quantile regression with reference to Denmark (largest survey response) were calculated. Results: There were no significant jurisdictional differences in the proportion diagnosed with symptoms on the Goff Symptom Index (53%; P = 0.179) or National Institute for Health and Care Excellence NG12 guidelines (62%; P = 0.946). Though the main diagnosis route consistently involved primary-care presentation (63–86%; P = 0.068), onward urgent referral rates varied significantly (29–79%; P < 0.001). In most jurisdictions, diagnostic intervals were generally shorter and other intervals, in particular, treatment longer compared to Denmark. Conclusion: This study highlights key intervals in the diagnostic pathway where improvements could be made. It provides the opportunity to consider the systems and approaches across different jurisdictions that might allow for more timely ovarian cancer diagnosis and treatment.
UR - http://www.scopus.com/inward/record.url?scp=85132311274&partnerID=8YFLogxK
U2 - 10.1038/s41416-022-01844-0
DO - 10.1038/s41416-022-01844-0
M3 - Journal article
C2 - 35618787
AN - SCOPUS:85132311274
SN - 0007-0920
JO - British Journal of Cancer
JF - British Journal of Cancer
ER -